cyrilzakka/clinical-trials huggingface dataset:
Ascending Ramus Versus Chin Cortical Plates for Reconstruction of Atrophic Maxilla

Assessment of ascending ramus cortical plate for reconstruction of atrophic maxillary ridges versus chin cortical plates (Randomized clinical trial)

Assessment of ascending ramus cortical plate for reconstruction of atrophic maxillary ridges versus chin cortical plates (Randomized clinical trial) To know what is better and more efficient chin or ascending ramus cortical plates.

Eligibility Criteria:
Inclusion Criteria:

* Patients with atrophic maxilla with residual bone height from 3 to 4mm.
* Both sexes

Exclusion Criteria:

* Intraoral soft and hard tissue pathology.
* Systemic condition that contraindicate implant basement.
* Psychiatric problems
Evaluation of the Use of a Urin Test Strip to Determine the Spread of Schistosoma Infections in Areas Where Schistosomiasis Infections Are Low in Kenya

The purpose of this study is to evaluate the use of a urine test strip in diagnose schistosoma mansoni in areas of Kenya where the rate of infections are low.

The hypothesis is that the urine strip test is a superior tool to the conventional parasitological tools used to diagnose schistosomiasis mansoni infections in area where there is low transmission

The study will compare the use of the urine test strip with the conventional method used and with a "golden standard" methode, in an area of Kenya where the infection transmission is low. Furthermore will the urine test strip be evaluatied in its ability to monitor the intensity of infections in school children before and after they are been treated for the infections.

A total of 1100 school children in the age between 10 and 18 years will be included in the study. Children have to submitt a stool and a urine sample on three consecutive days. Children who are found to be infected with the schistosomiasis parasite will be offered treatment.

Eligibility Criteria:
Inclusion Criteria:

* Children in the age between 10 and 18 years

Exclusion Criteria:

* Children younger then 10 years of age and children whos parent/guardians did not give informed consents for their participation in the study
The Effects of Manual Lymphatic Drainage and Kinesiotaping on Lower Extremity Edema

Significant trauma and muscular tightness often result during Total Knee Arthroplasty (TKA) surgery and thus act to restrict tissue fluid movement resulting with lower extremity edema. Kinesio Taping® is applied directly on the skin for restoration of normal fluid perfusion, removing congestion of lymphatic fluid or hemorrhages. In addition Manual Lymphatic Drainage (MLD) enhances blood circulation and stimulates the lymphatic movement and unblocks lymphatic territories. The aim of the study was to investigate the effectiveness of Kinesio Taping® and MLD in reducing postoperative edema and pain in the early stage after TKA.

Procedures: Patients who underwent unilateral TKA were randomized as Kinesio Taping® group, MLD group and control group. For all patients, postoperative rehabilitation program included early mobilization and physical therapy twice a day during the stay in orthopedic traumatology department. On the second day after surgery, lymphatic correction method was used on the Kinesio Taping® group patients and a standardized 30-minute MLD treatment was applied to the MLD group patients. Control group received only physiotherapy treatment. Circumference measurements were applied on preoperatively and the second, third, fourth day and 6th weeks after surgery. Knee Injury and Osteoarthritis Outcome Score (KOOS) was used to determine the functional outcomes on the 6th weeks after surgery. Repeated measures of variance analysis was used to determine time differences between groups.

Eligibility Criteria:
Inclusion Criteria:

* TKA surgery

Exclusion Criteria:

* active infection
* malignant tumor
* major cardiac pathology, or thrombus or venous obstruction that was pre-diagnosed or revealed on a routine preadmission hospital screening
Objective Assessment of Outcomes Following Immediate Lymphatic Reconstruction / LYMPHA

Immediate lymphatic reconstruction (ILR) is a novel surgical approach performed at the time of initial lymph node dissection with the goal of preventing lymphedema. It involves the identification of lymphatic channels that are transected after lymph node dissection and microsurgical anastomosis of one or more lymphatic channel with a local recipient vein to re-direct upper extremity lymphatic drainage. Although ILR carries significant promise in prevention of lymphedema, there is a lack of high-level evidence supporting its efficacy because it is a novel surgical technique that is only offered at a few centers and not routinely covered by insurance carriers yet. The University of Chicago Comprehensive Cancer Center (UCCCC) is one of the busiest microsurgery centers performing this procedure, and, as a Lymphedema Center of Excellence, is in a unique position to investigate the efficacy of ILR in preventing lymphedema. In addition, the University has access to a world class microbiome research facility and colleagues. There is no information on the skin microbiome of the axilla in patients undergoing treatment for breast cancer or those at risk for developing lymphedema. Further exploratory studies such as this in a diverse patient population may lead to practice changing research in our approach to lymphedema management and prevention. The purpose of this study is to determine the role of immediate lymphatic reconstruction and obtain objective data to correlate the existing, self-reported rates of lymphedema at the University of Chicago.


Eligibility Criteria:
Inclusion Criteria:

* All patients who were candidates for Immediate Lymphatic Reconstruction (ILR)

Exclusion Criteria:

* None
Spirometry and Methacholine Challenge Test in Asthmatic Children Age 3-6years

Rational: The possible contribution of methacholine challenge test via spirometry to the clinical diagnosis of young children with various respiratory symptoms, the most appropriate spirometry index, and the proper cutoff point concentration that will define airway sensitivity have not yet been explored. Objectives: To assess airway reactivity by spirometry in a large group of children aged 3-6years with various respiratory symptoms.

We aimed to gather information concerning methacholine challenge test performed in children previously diagnosed with asthma (asthmatics) and 48 had prolonged cough (coughers) from the pediatric clinic at Meyer Children's Hospital.

Tests were performed by inhalation of triple-concentration increments (0.06 to13.9mg/ml/methacholine).

Spirometry was determined at baseline and after each inhalation in duplicate sets. End of test was defined by a fall of 20%FEV1 baseline (PC20-FEV1). PC20-FEV1\<4.0mg/ml was considered positive). Results from the challenge were related to data from questionnaires concerning respiratory symptoms were analyzed at the end of the studies.

Eligibility Criteria:
Inclusion Criteria:

* age 3- to 6-years
* respiratory diseases who were highly indicative of asthma diagnosis according to GINA guidelines \[9\]
* cough duration of more than 4 weeks
* normal chest auscultation and baseline FEV1\>75% predicted for healthy preschool children, on the day of testing.

Exclusion Criteria:

* presence of other chronic respiratory conditions
* emergency room visit or the presence of respiratory infection within the last month
* oral or inhaled steroids or other anti-inflammatory medication taken in the last two weeks
* bronchodilator taken within 24-hours prior to the test.
Does Tranexamic Acid Administration Reduce Blood Loss During Head and Neck Surgery?

To Study whether infusion of Tranexamic Acid (a synthetic antifibrinolytic agent) reduces blood loss during head and neck surgery.

Blood and blood products are precious resources. Administration of blood and blood product carries with it the risk of postoperative bacterial infection1 and increased recurrence rates in certain types of cancers. Lower transfusion trigger, preoperative autologous blood donation with or without erythropoietin, intraoperative red blood cell salvage, regional anesthesia, controlled hypotension, and antifibrinolytic agents are all useful means to decrease the need for allogenic transfusions.

Tranexamic acid, a synthetic antifibrinolytic agent that binds to the lysine binding site of plasminogen and blocks the binding of plasminogen to the fibrin surface. Thus plasminogen activation is prevented and fibrinolysis is delayed. It has been used to reduce blood loss during coronary revascularization, orthotopic liver transplantation4, scoliosis correction surgery and other orthopedic procedures. The use of tranexamic acid intraoperatively has been shown to reduce blood loss by 25 - 40% in various studies. The primary concern when administering an antifibrinolytic drug is the potential increased incidence of thromboembolic events. A common misconception is that synthetic antifibrinolytic drugs increase blood clotting. The drugs do not alter blood clotting, but rather slow dissolution of blood clots. There is no data on the utility of tranexamic acid to reduce blood loss in head \& neck cancer surgery.

We wanted to compare Tranexamic Acid infusion to Saline (Placebo)infusion to see whether Tranexamic ACid Administration will reduce blood loss. Reduction in transfusion requirements will lead to reduced costs and possible reduction in complications of blood transfusion.

Eligibility Criteria:
Inclusion Criteria:

* All eligible previously untreated patients with resectable squamous cell carcinoma of the oral cavity
* Undergoing composite resection of the mandible along with neck dissection and requiring reconstructive procedures in the form of pedicled flaps.
* Patients who agree to participate by giving informed consent.

Exclusion Criteria:

* Coagulopathy form any cause (Abnormal coagulogram - prothrombin time (PT) \> 18 seconds or partial prothrombin time (PTT) \> 50 seconds, recent (\<5 days) acetylsalicylic acid ingestion, anticoagulant therapy (heparin, 4 hours preoperative or warfarin, 3 days preoperatively).
* Pre-existing renal dysfunction (serum creatinine 200 mmol/L),
* Known allergy to tranexamic acid,
* Peripheral vascular disease.
Helping Ethnic Minority in Hong Kong to Quit Smoking by Understanding Their Knowledge, Attitude and Behavior Related to Smoking

This study aims at understanding the needs and concerns of the ethnic minority in Hong Kong, including their behavior, attitudes, and experiences related to smoking and smoking cessation. Specifically, how the level of smoking-related knowledge among them differ from the rest of the Hong Kong people, will be explored. In addition, whether Hong Kong smoking policy influenced the smoking pattern of them will be investigated.

Cigarette smoking is the most significant preventable cause of death and disease, causing 6 million deaths annually worldwide. Despite the fact that tobacco use in Hong Kong has been decreased from 23.3% in 1982 to 10.1% in 2017, the remaining 620 600 daily smokers\[3\] cannot be overlooked or undervalued.

Hong Kong is a predominantly Chinese society, but it has a sizeable South Asian ethnic minority (EM). According to the Census \& Statistics Department, the number of ethnic minorities in Hong Kong increased significantly by 70.8% over the past 10 years. Nevertheless, few smoking and health promotion activities and smoking cessation services have been tailor-made for ethnic minorities in Hong Kong. The barrier of supplying smoking cessation service to the ethnic minority group is that their smoking motivation, willingness to quit, obstacles of quit smoking, attitude towards Hong Kong tobacco law and smoking cessation services are not sure. This will be the first research exploring their knowledge, attitude and experience of cigarette smoking.

Eligibility Criteria:
Inclusion Criteria:

* Only smokers with South Asian(Pakistani, Indian, or Nepalese)backgrounds
* Willing to participate
* aged 18 years or above
* able to speak English
* smoke at least one cigarette per day for the past 3 months

Exclusion Criteria:

* Domestic workers, asylum seekers, refugees, or illegal immigrants, individuals with other ethnic backgrounds, i.e., Africans
* Cannot speak English
* poor cognitive state or active psychotic symptoms, i.e. hallucination, illusion and delusion, noted in the medical records.
Thymic Tolerance in Pediatric Heart Transplantation

The investigators hypothesize that injecting donor bone marrow cells into the recipient thymus gland at the time of heart transplantation in children will prove to be feasible and safe. They further hypothesize that recipients receiving donor bone marrow will experience less acute rejection events with reduced long-term requirements for immunosuppressive medications when compared to controls who do not receive marrow but who are managed under an identical immunosuppressive protocol.


Eligibility Criteria:
Inclusion Criteria:

* Less than 21 years of age at listing
* Listed for primary orthotopic heart transplant at Children's Hospital of Pittsburgh, between 04/01/04 and 03/31/08

Exclusion Criteria:

* History of prior transplant
* Listed for multi-organ transplant
* Sensitized against human HLA tissue types
* Documentation of total thymomectomy during a prior surgery
The Influence of Cognitive Status on Walking Abilities After Femoral Neck Fracture

Introduction: Femoral neck fracture is a devastating injury with serious medical and social consequences. One third of these patients have some degree of impaired cognitive status. Despite of this, a high proportion of hip fracture trials exclude patients with cognitive impairment. The investigators aimed to evaluate whether moderate to severe cognitive impairment could predict walking ability, quality of life, functional outcome, reoperations and mortality in elderly patients treated with hemiarthroplasty.

Methods: This cohort study included a consecutive series of 188 patients treated with hemiarthroplasty for an displaced femoral neck fracture. Patient were assessed for estimated preoperative and 1 year postoperatively with regard to walking abilities, cognitive status, quality of life with EQ-5D and hip function with Harris hip score.


Eligibility Criteria:
Inclusion Criteria:

* 65 year or above
* Displaced femoral neck fracture
* Treated with a hemiarthroplasty

Exclusion Criteria:

* Pathological fractures
* Bilateral femoral neck fractures
* Bed-ridden patients.
Epidemiologic Follow Up Study of Newly Diagnosed Epilepsy Among Seniors

The purpose of this proposed research is to identify individuals in southeastern Arizona aged 65 years and older who have new onset seizures (or newly diagnosed epilepsy) and monitor them for at least two years. In doing so the investigators will be able to describe the public health burden of this condition and to identify factors that predict clinical outcomes and health care needs in this population, using quantitative, administrative, and qualitative data. The aims of this proposed research are 1) to determine the two-year incidence of newly diagnosed epilepsy in the target population, 2) describe health care resource utilization of the target population using Medicare data, 3) validate the use of Medicare beneficiary data to estimate incidence of epilepsy, and 4) describe the burden of this condition in different ethnic groups.

Seniors who have had new onset seizures or newly diagnosed epilepsy will be recruited from emergency departments (EDs), neurology clinics, primary care clinics (including geriatric clinics), and other service providers from networks maintained by the Area Agencies on Aging that serve seniors in southeastern Arizona. Data will be collected in the form of bi-annual surveys,administrative data (from Medicare), in-depth interviews, and focus groups. Medicare data will be used to describe and evaluate the likelihood of being hospitalized or admitted to a long-term facility within two years of being diagnosed, medication adherence and persistence, and comparing the cost of care between the newly-diagnosed seniors with epilepsy and comparable seniors who do not have epilepsy. The feasibility and validity of using the Medicare claims data to estimate newly diagnosed epilepsy will also be assessed. Finally, the impact of epilepsy on health related quality of life, mental health, perceived stigma, and family and caregivers will also be evaluated through surveys and qualitative data collection methods, and ethnic differences will also be described.

Eligibility Criteria:
Inclusion Criteria:

* Aged 65 years or older
* New onset seizure or newly diagnosed epilepsy as of October 2010
* Is a resident of Pima, Cochise or Santa Cruz County

Exclusion Criteria:

* Seizure dues to hyponatremia, hypoglycemia, alcohol use (with no evidence of other seizures)
Radiological Evaluation of the Penis Before and After a Botox Injection

The goal of this clinical trial is to find out if injecting Botox into men with erectile dysfunction makes their penis less stiff and gives them better erections. This will be done using a new ultrasound method. The main questions it tries to answer are: Is Botox injection safe and effective for men suffering from erectile dysfunction who failed other treatment methods? Does this new method have any radiological criteria for penile tissues? • If Botox is injected into the penis, is there a cut-off number for this technique that shows how much better things are before and after? Before and after treatment, participants will rate how much their erections have improved, and investigators will connect their answers to the findings


Eligibility Criteria:
Inclusion Criteria:

* Men with ED not responding to oral PDE5Is.

Exclusion Criteria:

* Patients with penile prostheses.
* Patients diagnosed with Peyronie's disease.
* Non-vascular erectile dysfunction.
* Medical comorbidities that would limit the benefit of ICI such as uncontrolled diabetes mellitus, significant cardiovascular disease interfering with sexual activity, unstable psychiatric conditions, and the presence of anatomical, hormonal, or neurological abnormalities that would significantly impair erectile function.
* Patients with a history of radical pelvic surgery.
* Pelvic or spinal trauma
Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minimal Residual Disease (MRD)

This is a single-arm, open-label, multi-center phase I study using blinatumomab for pediatric B-cell acute lymphoblastic leukemia patients with positive of minimal residual disease. 1 Cycle of blinatumomab treatment followed by hematopoietic stem cell transplantation. Blinatumomab has approved to treat adults and children with B-cell precursor ALL who are in remission but still have MRD. However, data on the effects and safety of blinatumomab in children with B-precursor ALL with MRD positive are insufficient.


Eligibility Criteria:
Inclusion Criteria:

* Immunophenotypic evidence of Cluster of Differentiation 19 (CD19) positive B precursor ALL
* Age \<18 years at the time of informed consent/assent
* B cell precursor ALL in first or later hematologic complete remission (CR) defined as less than 5% blasts in bone marrow after at least three intense chemotherapy blocks
* Persistent or recurrent MRD ≥10\^-4 in an assay with a minimum sensitivity of 10\^-5 before hematopoietic stem cell transplantation
* Bone marrow function as defined below: Absolute neutrophil count ≥1,000/μL, Platelets ≥50,000/μL (transfusion permitted), Hemoglobin level ≥9 g/dL (transfusion permitted)
* Renal and hepatic function as defined below: Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), and alkaline phosphatase (AP) \< 2 x upper limit of normal (ULN), Total bilirubin \<1.5 x ULN, Creatinine clearance ≥ 50 mL/min
* Negative HIV test, negative hepatitis B (HBsAg) and hepatitis C virus (anti-HCV) test
* Negative pregnancy test in women of childbearing potential

Exclusion Criteria:

* Presence of circulating blasts or current extramedullary involvement by ALL
* History of relevant central nervous system (CNS) pathology or current relevant CNS pathology (e.g. seizure, epilepsy, paresis, aphasia, stroke, severe brain injuries, dementia, cerebellar disease, organic brain syndrome, psychosis) with the except of CNS leukemia that is well controlled with intrathecal therapy
* Current infiltration of cerebrospinal fluid by ALL
* History of or active relevant autoimmune disease
* Systemic cancer chemotherapy within 2 weeks prior to study treatment (except for intrathecal prophylaxis)
* Radiotherapy within 4 weeks prior to study treatment
* Autologous hematopoietic stem cell transplantation (HSCT) within six weeks prior to study treatment
* Therapy with monoclonal antibodies (rituximab, alemtuzumab) within 4 weeks prior to study treatment
* Treatment with any investigational product within 4 weeks prior to study treatment
* Known hypersensitivity to immunoglobulin or to any other component of the study drug formulation
* Active malignancy other than ALL with the exception of basal cell or squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix
* Active infection, any other concurrent disease or medical condition that are deemed to interfere with the conduct of the study as judged by the investigator
The Biomechanical Mechanism for Gait and Plantar Pressure Changes After Posterior Cruciate Ligament Rupture and Reconstruction

Investigating the biomechanics for the PCL ruptured or reconstructed patients during walking, jogging, cutting, jumping. To establish a knee joint biomechanical evaluation model to quantify and evaluate the plantar pressure information under dynamic load-bearing state after PCL fracture. Provide a precise basis for the biomechanical state of the knee, and establish a clinically practical automatic analysis of plantar pressure information and an expert diagnostic system.

Background: The posterior cruciate ligament (PCL) is an essential structure in knee stabilization. Knee cartilage degeneration after a PCL injury has been reported in several studies. Understanding the changes in movement patterns of patients with PCL ruptures could help clinicians make specific treatment protocols to restore patients' sporting ability and prevent joint degeneration. However, the kinematics and kinetics of the lower limb in patients with PCL injuries are still not clear.

Methods: Three-dimensional gait analysis system, force plate, electromyography will be used for 55 healthy male participants (control group) and 55 male patients with isolated PCL-deficiency (PCL-d group) during walking, jogging, cutting, jumping. Repeated measurement two-factor analysis of variance will be performed to determine differences between involved and uninvolved legs in the PCL-d group and control group at different rehabilitation times (prior reconstruction surgery, 6 months, and 1-year post PCL reconstruction surgery). Three-dimensional gait analysis and computer-aided analysis technology of plantar pressure information were used to study the changes of PCL after fracture and reconstruction. Based on the plantar pressure information, the movement parameters, and individual attribute parameters, establish a knee joint biomechanical evaluation model to quantify and evaluate the plantar pressure information under dynamic load-bearing state after PCL fracture. Provide a precise basis for the biomechanical state of the knee, and establish a clinically practical automatic analysis of plantar pressure information and an expert diagnostic system.

Eligibility Criteria:
Inclusion Criteria:

* age of 18-45 years old
* Isolated PCL rupture patients: The inclusion criteria included an isolated PCL rupture of at least 3 months' duration.
* Healthy volunteers: no history of neuro or musculoskeletal system injury that may affect the movements.

Exclusion Criteria:

* additional knee ligament or meniscal damage
* severe damage to the ipsilateral hip, ankle joint, or contralateral lower limb (ligament ruptures or bone fractures)
* age \>50 years (to avoid age-induced osteoarthritis interference)
* any cartilage injury grade \>2 according to the Outerbridge classification
* Tegner score18 \<3